BeOne Medicines AG

BeOne Medicines AG is an oncology company that discovers and develops treatments for cancer patients globally. Its commercial-stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for various blood cancers, and TEVIMBRA, an anti-PD-1 antibody immunotherapy for solid tumors and blood cancers. Other marketed drugs are SYLVANT for multicentric Castleman disease, BAITUOWEI for premenopausal and perimenopausal breast cancer, and PARTRUVIX for solid tumors. The company also has a robust clinical pipeline, including Sonrotoclax (Bcl-2 inhibitor), BGB-16673 (BTK degrader), and several bispecific antibodies and ADCs. Additionally, it has preclinical programs and partnerships with Amgen, BMS, Bio-Thera, and EUSA Pharma.

BeOne Medicines AG is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ONC. Its securities trade in US Dollars (USD), as the exchange is based in the United States. The company is headquartered in Switzerland, but its stock is traded on a US exchange, making it accessible to international investors. The listing on NasdaqGS indicates that the company meets the exchange's stringent financial and liquidity requirements.

BeOne Medicines AG operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for cancer. The company's work involves both small molecule drugs and biologics, including targeted inhibitors, immunotherapies, and antibody-drug conjugates. Its industry classification reflects its primary activity of using biological and chemical processes to create treatments for oncological diseases.

BeOne Medicines AG is headquartered in Switzerland, a country known for its strong pharmaceutical and biotech sectors. The company serves patients globally, as indicated by its description of discovering and developing treatments for cancer patients worldwide. Its commercial products are available in multiple regions, and its clinical trials are likely conducted internationally. The company's partnerships with global pharmaceutical firms like Amgen and BMS further support its international reach.

BeOne Medicines AG's portfolio includes both commercial and clinical-stage products. Key commercial products are BRUKINSA (BTK inhibitor for blood cancers), TEVIMBRA (anti-PD-1 immunotherapy), SYLVANT (for multicentric Castleman disease), BAITUOWEI (for breast cancer), and PARTRUVIX (for solid tumors). In the pipeline, notable candidates are Sonrotoclax (Bcl-2 inhibitor), BGB-16673 (BTK degrader), and several bispecific antibodies like BG-T187 (anti-EGFRxMET) and Zanidatamab (HER2-targeted). The company also develops ADCs such as BG-C477 (anti-CEA) and preclinical programs. These products target a range of hematologic and solid tumor cancers.